Crohn's colitis

Summary

Crohn’s colitis (MONDO:0005532) is a disease and 16 clinical trials. Top therapeutic interventions include remestemcel-l. A subtype of Crohn disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 16

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Crohn’s colitis
Mondo ID	MONDO:0005532
EFO	EFO:0005622
DOID	DOID:0060192
NCIT	C35211
UMLS	C0156147
MedGen	57618
Is cancer (heuristic)	no

Also known as: Crohn colitis

Disease family

This is a subtype of Crohn disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › inflammatory bowel disease › Crohn disease › Crohn’s colitis

Related subtypes (4): oral Crohn disease, perianal Crohn disease, small bowel Crohn disease, Crohn disease of the esophagus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 16.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	14
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05194007	PHASE2/PHASE3	COMPLETED	Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease
NCT04548583	PHASE1/PHASE2	TERMINATED	Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn’s Colitis
NCT05332639	Not specified	RECRUITING	Personalized Risk Estimation for Crohn’s Disease (PRE-Crohn’s): Implementation and Feasibility
NCT06555042	Not specified	RECRUITING	Investigation of VAP-1 Expression and Tissue Blood Flow by PET-MRI in Patients With Crohn’s Disease
NCT06655415	Not specified	RECRUITING	Family Members At INcreased-risk for Developing Inflammatory Bowel Disease
NCT01505842	Not specified	UNKNOWN	Chromoendoscopy for Dysplasia Detection in Chronic Inflammatory Bowel Disease
NCT02033408	Not specified	COMPLETED	Manipulating the Microbiome in IBD by Antibiotics and FMT
NCT02822352	Not specified	COMPLETED	RCT: HDWL vs Virtual Chromoendoscopy in the Detection of Intraepithelial Neoplasia in Longstanding Colitis
NCT04031469	Not specified	SUSPENDED	A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
NCT04100005	Not specified	WITHDRAWN	A Pilot Study to Explore the Role of Gut Flora in Crohn’s Disease
NCT04191655	Not specified	COMPLETED	High Definition Colonoscopy (HDC) vs. Dye Spraying Chromo-colonoscopy (DSC) in Screening Patients With Long-standing Inflammatory Bowel Disease (IBD)
NCT04695184	Not specified	UNKNOWN	Subjective Near-infrared Fluorescence Guidance in Perfusion Assessment of Ileal Pouch Formation and Ileal-pouch-anal Anastomosis
NCT04695964	Not specified	UNKNOWN	Objective Perfusion Rate Assessment by Near-infrared Fluorescence in Ileal Pouch Formation and Ileal-pouch-anal Anastomosis
NCT04924543	Not specified	COMPLETED	OPtical Diagnosis Training to Improve Dysplasia Characterisation in IBD
NCT05663671	Not specified	UNKNOWN	Evaluate Established Anti-DEFA5 mAbs Diagnostic Efficacy and Safety in IBD
NCT06116331	Not specified	UNKNOWN	The Mind-Body IBD Study: Understanding the Mind-body Connection in IBD

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
REMESTEMCEL-L	3	1